Profitability Ratios
| Ratio |
Value |
| GP Margin |
66.4% |
| EBIT Margin |
-1.4% |
| EBITDA Margin |
1.4% |
| Operating Margin |
5.6% |
| Pretax Margin |
-8.4% |
| Cont. Ops Margin |
-66.2% |
| Net Margin |
-66.2% |
| Bottom Line Margin |
-66.2% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
7.85 |
| Quick Ratio |
7.85 |
| Solvency Ratio |
-0.940 |
| Cash Ratio |
6.27 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.48 |
| Forward PEG |
0.48 |
| Price/Book |
13.19 |
| Price/Sales |
9.38 |
| Price/FCF |
113.87 |
| Price/Op Cash Flow |
91.60 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.3367 |
| Debt/Equity |
0.6565 |
| Debt/Capital |
0.3963 |
| Long-Term Debt/Capital |
0.3962 |
| Financial Leverage |
1.95 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
1.76 |
| Operating Cash Flow Ratio |
0.654 |
| Operating Cash Flow/Sales |
10.2% |
| Free Cash Flow/Operating Cash Flow |
80.4% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-8.04 |
| Interest Coverage |
0.7935 |
| Short-Term Operating Cash Flow Coverage |
492.04 |
| Operating Cash Flow Coverage |
0.22 |
| Capital Expenditure Coverage |
5.11 |
| Dividend + Capital Expenditure Coverage |
5.11 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
2.88 |
| EPS |
-1.905 |
| Debt/Share |
1.5437 |
| Cash/Share |
2.83 |
| Book Value/Share |
2.04 |
| Tangible BV/Share |
1.98 |
| Equity/Share |
2.04 |
| Operating Cash Flow/Share |
0.295 |
| Capital Expenditure/Share |
0.058 |
| FCF/Share |
0.237 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
7.901 |
| Earnings Before Tax/EBIT |
-1.509 |
| Price/Fair Value |
13.19 |
| Debt/Market Cap |
0.0498 |
| Effective Tax Rate |
-690.1% |
| Enterprise Value Multiple |
632.55 |
CAI - Caris Life Sciences, Inc.